<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00194324</url>
  </required_header>
  <id_info>
    <org_study_id>708889</org_study_id>
    <secondary_id>RRU010</secondary_id>
    <nct_id>NCT00194324</nct_id>
  </id_info>
  <brief_title>Effect of Exercise on Spread of the Miconozole Nitrate OVULE in the Vagina</brief_title>
  <official_title>Vaginal Imaging Study to Evaluate the Effect of Exercise on the Distribution of Miconozole Nitrate OVULE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Johnson &amp; Johnson</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study uses MRI to detect the spread of the Miconozole Nitrate OVULE within the vagina.
      The effect of moderate amounts of physical activity on the spread will be evaluated, and
      compared to no physical activity.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">October 2004</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare between exercise and no exercise:</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Time needed for the capsule to dissolve;</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantify and describe product distribution at 20 minute intervals within the first 90 minutes after insertion;</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantify systemic levels of miconozole nitrate 90 minutes and 24 hours after insertion;</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantify amount of miconozole nitrate in the vagina 90 minutes and 24 hours after insertion</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Product distribution will be assessed by:</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Linear spread from the cervix covered by the product;</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of maximal linear spread from the cervix;</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surface area covered by the product;</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of maximal surface contact;</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence bare spots in coating;</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of product outside the introitus</measure>
  </secondary_outcome>
  <enrollment>12</enrollment>
  <condition>Health</condition>
  <condition>Vulvovaginal Candidiasis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Miconazole nitrate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Magnetic resonance imaging</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Moderate levels of exercise</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Not at risk for pregnancy

          -  Willing to abstain from intercourse 24 hours prior to MRI

          -  Regular menstrual cycles (every 23-38 days)

          -  At least 10 weeks from most recent pregnancy outcome and had 2 spontaneous menstrual
             cycles since

          -  Normal pap smear within previous 12 months

          -  Negative test for yeast, bacterial vaginosis and trichomonas

          -  Not allergic to any component of the formulation

          -  No contraindications to MRI

          -  Not participated in another investigational trial within 30 days

          -  No history of condition, or finding on exam, that, in the opinion of the investigator,
             would make participation unsafe for the volunteer or complicate interpretation of the
             data
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kurt T Barnhart, MD, MSCE</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania Reproductive Research Unit</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <last_update_submitted>August 8, 2011</last_update_submitted>
  <last_update_submitted_qc>August 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 9, 2011</last_update_posted>
  <responsible_party>
    <name_title>Kurt T Barnhart, MD, MSCE</name_title>
    <organization>University of Pennsylvania</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candidiasis</mesh_term>
    <mesh_term>Candidiasis, Vulvovaginal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Miconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

